StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
6
Publishing Date
2022 - 03 - 08
1
2021 - 12 - 13
1
2021 - 09 - 14
2
2021 - 08 - 19
1
2021 - 08 - 18
1
Sector
Health technology
6
Manufacturing
1
Tags
Abbvie
78
Active
14
Aesthetic
22
Alliances
19
America
43
Antibody
17
Application
15
Approval
37
Atopic dermatitis
10
Biomidwest
43
Biotech-beach
10
Business
12
Cancer
53
Cd20
13
Clinical-trials-phase-iii
26
Collaboration
23
Conference
32
Contract
13
Deadline
11
Dermatitis
14
Disease
65
Drug
75
Duobody
13
Earnings
22
Europe
16
Events
24
Expected
18
Eye
17
Fda
42
Financial
26
Financial results
12
Genetown
11
Global
113
Growing
24
Growth
174
Health
20
Key
12
Leukemia
16
Market
388
Meeting
13
Migraine
23
N/a
789
Pharma
18
Pharmaceuticals
11
Phase 3
30
Positive
31
Reach
16
Report
97
Research
81
Results
80
Rinvoq
28
Risankizumab
14
Set
20
Skyrizi
16
Therapeutics
88
Therapy
40
Treatment
117
Trial
32
Ulcerative colitis
14
Year
12
Entities
Abbvie inc.
6
Amgen inc.
1
Astellas pharma inc
1
Astrazeneca plc
1
Coherus biosciences, inc.
5
Novartis ag
1
Sanofi
1
Symbols
A
3
ABBV
6
ABT
2
ADAG
2
ADXS
1
AGNPF
2
ALPMF
1
ALPMY
1
ALRN
2
AMGN
16
ARAY
1
AZN
10
AZNCF
5
BBIO
1
BCTX
1
BDSX
4
BGNE
10
BIOC
4
BMY
1
BNR
1
BPMC
2
BYSI
6
CADL
1
CHRS
6
DGX
2
GH
8
GLTO
2
GMAB
3
GNMSF
2
GNPX
9
GTHX
5
HARP
3
HCM
4
IBRX
2
INCY
6
IOVA
3
JAZZ
5
JNJ
15
LIXT
3
LLY
11
LTRN
2
MRTX
7
MRUS
2
NEO
4
NSTG
4
NVCR
6
NVS
3
NVSEF
2
ONTX
2
PFE
2
QGEN
4
REGN
4
SNY
13
SNYNF
5
SRNE
3
TMO
3
TPTX
4
VCYT
7
VSTM
2
ZLAB
2
Exchanges
Nasdaq
6
Nyse
6
Crawled Date
2022 - 03 - 08
1
2021 - 12 - 13
1
2021 - 09 - 14
2
2021 - 08 - 19
1
2021 - 08 - 18
1
Crawled Time
02:00
3
08:00
1
21:00
1
23:00
1
Source
www.globenewswire.com
5
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Lung cancer
symbols :
ABBV
save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published:
2022-03-08
(Crawled : 08:00)
- prnewswire.com
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
22.78%
|
O:
-2.09%
H:
5.03%
C:
0.85%
ALPMY
|
News
|
$9.49
-1.11%
480K
|
Manufacturing
|
-40.35%
|
O:
1.01%
H:
0.81%
C:
-0.06%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
17.97%
|
O:
-4.98%
H:
0.0%
C:
0.0%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
14.12%
|
O:
0.29%
H:
0.6%
C:
-1.24%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-3.62%
|
O:
3.03%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
23.97%
|
O:
-0.44%
H:
0.0%
C:
0.0%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
18.14%
|
O:
0.35%
H:
0.0%
C:
0.0%
drug
cel
lung cancer
cancer drug
cancer
growth
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
36.86%
|
O:
1.07%
H:
0.0%
C:
0.0%
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-87.03%
|
O:
-0.83%
H:
0.0%
C:
0.0%
hoice-01
treatment
trial
lung cancer
positive
therapy
bioscience
results
cancer
phase 3
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published:
2021-09-14
(Crawled : 02:00)
- globenewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
57.74%
|
O:
0.47%
H:
0.07%
C:
-1.4%
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-86.52%
|
O:
0.31%
H:
0.49%
C:
-0.86%
treatment
lung cancer
positive
results
cancer
conference
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published:
2021-09-14
(Crawled : 02:00)
- globenewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
57.74%
|
O:
0.47%
H:
0.07%
C:
-1.4%
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-86.52%
|
O:
0.31%
H:
0.49%
C:
-0.86%
treatment
lung cancer
positive
results
cancer
conference
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published:
2021-08-19
(Crawled : 02:00)
- globenewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
44.55%
|
O:
-0.92%
H:
2.37%
C:
1.48%
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-84.58%
|
O:
1.27%
H:
8.73%
C:
1.47%
treatment
lung cancer
positive
therapy
results
cancer
phase 3
trial
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published:
2021-08-18
(Crawled : 23:00)
- globenewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
44.55%
|
O:
-0.92%
H:
2.37%
C:
1.48%
CHRS
|
$2.03
-6.88%
-7.39%
720K
|
Health Technology
|
-84.58%
|
O:
1.27%
H:
8.73%
C:
1.47%
treatment
lung cancer
positive
therapy
results
cancer
phase 3
trial
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.